Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2021 - 2026)

Zentalis Pharmaceuticals has reported Receivables - Accured over the past 6 years, most recently at $2.1 million for Q1 2026.

  • For Q1 2026, Receivables - Accured fell 23.27% year-over-year to $2.1 million; the TTM value through Mar 2026 reached $2.1 million, down 23.27%, while the annual FY2025 figure was $1.9 million, 34.49% down from the prior year.
  • Receivables - Accured for Q1 2026 was $2.1 million at Zentalis Pharmaceuticals, up from $1.9 million in the prior quarter.
  • Over five years, Receivables - Accured peaked at $3.3 million in Q4 2023 and troughed at $266000.0 in Q1 2022.
  • A 5-year average of $1.9 million and a median of $2.1 million in 2026 define the central range for Receivables - Accured.
  • Biggest five-year swings in Receivables - Accured: surged 719.48% in 2024 and later crashed 34.83% in 2025.
  • Year by year, Receivables - Accured stood at $508000.0 in 2022, then skyrocketed by 556.89% to $3.3 million in 2023, then fell by 11.81% to $2.9 million in 2024, then tumbled by 34.49% to $1.9 million in 2025, then increased by 8.97% to $2.1 million in 2026.
  • Business Quant data shows Receivables - Accured for ZNTL at $2.1 million in Q1 2026, $1.9 million in Q4 2025, and $2.2 million in Q3 2025.